Skip to content

Red Cell Distribution Width to Albumin Ratio as a Predictor of Short Term Mortality of Patients admitted for Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Utility of Red Cell Distribution Width to Albumin Ratio (RAR) to Predict Short Term Mortality in Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Prospective Observational Study - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/05/067962
Enrollment
83
Registered
2024-05-28
Start date
Unknown
Completion date
Unknown
Last updated
2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J441- Chronic obstructive pulmonary disease with (acute) exacerbation

Interventions

Intervention1: NIL: NIL

Sponsors

None
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients requiring hospital admission for ECOPD (moderate to severe)

Exclusion criteria

Exclusion criteria: 1. Patients with a known hematologic disease. 2. Pregnancy 3. Liver disease 4. Diabetic ketoacidosis 5. Acute stroke 6. Severe malnutrition 7. Refusal to consent for the study. 8. Patients refusing available treatment modalities advised by the physician including invasive mechanical ventilation, renal replacement therapy etc

Design outcomes

Primary

MeasureTime frame
Diagnostic profile and threshold of Red cell distribution width to albumin ratio (RAR) (at admission) that predicts 28-day all-cause mortality in patients admitted with ECOPD.Timepoint: Admission to 28-days post-admission or death, whichever is earlier

Secondary

MeasureTime frame
Blood or component transfusionTimepoint: Admission to 28-days post-admission or death, whichever is earlier;Hospital mortalityTimepoint: Admission to 28-days post-admission or death, whichever is earlier;ICU complicationsTimepoint: Admission to 28-days post-admission, ICU discharge or death, whichever is earlier;ICU mortalityTimepoint: Admission to 28-days post-admission, ICU discharge or death, whichever is earlier;Length of hospital stayTimepoint: Admission to 28-days post-admission, hospital discharge or death, whichever is earlier;Length of ICU stayTimepoint: Admission to 28-days post-admission, ICU discharge or death, whichever is earlier;Need for invasive mechanical ventilationTimepoint: Admission to 28-days post-admission or death, whichever is earlier;Need for recurrent invasive ventilationTimepoint: Admission to 28-days post-admission or death, whichever is earlier;Need for renal replacement therapyTimepoint: Admission to 28-days post-admission or death, whichever is earlier;New onset bacteraemia/fungemiaTimepoint: Admission to 28-days post-admission or death, whichever is earlier;NIV failureTimepoint: Admission to 28-days post-admission, ICU discharge or death, whichever is earlier;Number of vasopressor free daysTimepoint: Admission to 28-days post-admission or death, whichever is earlier;Number of ventilator free daysTimepoint: Admission to 28-days post-admission or death, whichever is earlier;Organ failure free daysTimepoint: Admission to 28-days post-admission or death, whichever is earlier;SOFA, APACHE II, and CCI ScoreTimepoint: At Admission

Countries

India

Contacts

Public ContactDr Gaurav Jain

All India Institute of Medical Sciences, Rishikesh

gauravhld@gmail.com8808631209

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026